Form 4 NxStage Medical, Inc. For: Feb 09 Filed by: Turk Joseph E Jr
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- US stock futures tumble as Trump says Iran deal is 'over', oil climbs
- Oil jumps over 6% to two-week high after Trump says deal with Iran 'over'
- Citi says SpaceX stock has path to $900+ valuation. Here’s how
- Tesla stock target lifted at RBC on potential SpaceX merger
- Short squeezes more likely than widespread selling: Citi
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Selloff in NxStage Medical (NXTM) Seems 'Excessive'; BTIG Reaffirms at 'Buy'
February 11, 2016 9:48 AM ESTBTIG is out in defense of NxStage Medical, Inc. (NXTM) following the company's Q4, FY16 results reported on Wednesday. The firm rates NxStage at Buy with a price target of $27.
Analyst Sean Lavin noted that NxStage posted FY16 revenue of $336 million, which exceeded the company's outlook of $332 - $333 million. But, a... More
